LKFT — Lakefront Biotherapeutics NV Share News
0.000.00%
Last trade - 00:00- €1.77bn
- -€467.06m
- €1.11bn
Brief: Landmark Bio to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
Galapagos rises on narrowing losses, guidance confirmation
Galapagos NV reports results for the quarter ended in September - Earnings Summary
Brief: Galapagos Reports Third Quarter 2023 Results And Releases New Data From Car-T Studies For Presentation At Ash 2023
Galapagos NV expected to post a loss of 96 cents a share - Earnings Preview
Brief: Galapagos Signs Letter Of Intent To Transfer Jyseleca Business To Alfasigma
Europe Research Roundup: Air Liquide, Galapagos NV, Pennon Group
Citi downgrades Galapagos on Jyseleca commercial outlook, M&A pace
Brief: Galapagos Cuts Jyseleca FY Sales Guidance
Galapagos slips on drug Jyseleca sales guidance cut
Galapagos NV expected to post a loss of 83 cents a share - Earnings Preview
KBC ups Galapagos on Cocoon device potential, shares top AEX
Brief: Galapagos Appoints Thad Huston As CFO
Brief: Ecor1 Capital Llc Reports 9.9% Passive Stake In Galapagos NV As Of June 7, 2023 - SEC Filing
Europe Research Roundup: Bat, JD Wetherspoon, Mitchells & Butlers
Brief: Galapagos Announces Start Of Phase 2 Study With Selective TYK2 Inhibitor, GLPG3667
Europe Research Roundup: Adidas, Ferrari, Nexans
Brief: Galapagos Q1 Revenue Up 31% To EUR 178.9 Mln
Brief: Galapagos Initiates Late Stage Study With Filgotinib In Patients With Active Axial Spondyloarthritis